An introduction to the genetics of epilepsy — from neonatal-onset epileptic encephalopathies and ion channelopathies to inborn errors of metabolism causing seizures, with a practical focus on genetic diagnosis and treatment implications.
Tags: Neurogenetics · Advanced
Epilepsy affects approximately 1–2% of the population, and genetic factors are implicated in up to 70% of all epilepsy. The International League Against Epilepsy (ILAE) 2017 classification recognizes 'genetic' as one of the primary epilepsy etiologies — defined as epilepsy resulting directly from a known or presumed genetic cause. The genetic architecture ranges from rare, highly penetrant single-gene disorders (causing severe early-onset epileptic encephalopathies) to common polygenic forms of epilepsy influenced by many variants of small effect.
Key Points
The neonatal and early infantile period is associated with a distinct and often devastating set of epileptic encephalopathies. The genetic differential for neonatal seizures is broad and includes ion channelopathies, cortical malformation genes, inborn errors of metabolism, and imprinting disorders. Identifying the genetic cause is urgent because several conditions respond to specific treatments.
Key Points
Inborn errors of metabolism (IEM) represent a diverse group of genetic disorders caused by enzyme deficiencies in metabolic pathways. Individually rare, collectively they account for a significant fraction of neonatal and infantile epilepsy — and crucially, many are amenable to specific treatments. A systematic metabolic workup is mandatory for any infant with unexplained early-onset seizures. For comprehensive coverage of metabolic disorders beyond epilepsy, see the Inborn Errors of Metabolism module.
Key Points
Genetic testing in epilepsy frequently yields variants of uncertain significance (VUS) and results that require careful clinical contextualization. The clinician must integrate variant classification, gene-phenotype fit, inheritance pattern, and functional data to determine whether a genetic finding explains the patient's epilepsy. Understanding common pitfalls prevents both under- and over-interpretation of genetic results.
Key Points
Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an autosomal recessive disorder caused by biallelic variants in ALDH7A1, encoding antiquitin — an enzyme in the cerebral lysine degradation pathway. Antiquitin deficiency causes accumulation of alpha-aminoadipic semialdehyde (AASA) and its cyclic form piperideine-6-carboxylate (P6C), which inactivates pyridoxal-5-phosphate (PLP) by forming a Knoevenagel condensation product. The resulting cerebral PLP deficiency causes seizures.
Key Points
1. A child with SCN2A epilepsy and seizure onset at 18 months is started on carbamazepine (a sodium channel blocker). Her seizures worsen significantly over the following weeks. Based on the age of onset, what is the most likely explanation?
SCN2A is a critical gene to understand in precision epilepsy because the same gene causes two opposite treatment scenarios depending on the variant's functional effect. Early-onset (<3 months) SCN2A epilepsy is typically caused by gain-of-function variants that increase sodium channel activity — sodium channel blockers are effective here because they counteract the excess activity. Late-onset (>3 months) SCN2A epilepsy is more often caused by loss-of-function variants that reduce sodium channel activity — adding sodium channel blockers further reduces the already-diminished channel function, worsening seizures. Age of onset serves as a practical clinical proxy for predicting the variant's functional consequence and guiding initial treatment.
2. A neonate with KCNQ2 epileptic encephalopathy is initially treated with phenobarbital alone, with incomplete seizure control. The genetics team recommends adding a sodium channel blocker. Why are sodium channel blockers specifically effective in KCNQ2 loss-of-function epilepsy?
KCNQ2 encodes the Kv7.2 voltage-gated potassium channel subunit. The M-current (conducted by Kv7.2/Kv7.3 heteromers) acts as a 'brake' on neuronal excitability — it stabilizes the resting membrane potential and prevents repetitive firing. Loss-of-function variants reduce this braking mechanism, leading to neuronal hyperexcitability and seizures. Sodium channel blockers (carbamazepine, phenytoin) are effective because they reduce sodium-dependent neuronal firing through a complementary mechanism, compensating for the lost potassium channel brake. Phenobarbital enhances GABA-A inhibition, which helps but does not directly address the excitability imbalance as effectively. This is why KCNQ2 neonatal encephalopathy often responds best to sodium channel blockers.
3. A toddler with epilepsy, acquired microcephaly, and developmental delay has a dramatic improvement in seizure control after starting a ketogenic diet. Which diagnosis does this treatment response most strongly suggest, and what confirmatory test should be ordered?
The triad of infantile-onset epilepsy, acquired microcephaly, and developmental delay — with a dramatic response to ketogenic diet — is characteristic of GLUT1 deficiency syndrome caused by SLC2A1 haploinsufficiency. The GLUT1 transporter normally carries glucose across the blood-brain barrier. When it is deficient, the brain is deprived of its primary fuel. The ketogenic diet provides ketone bodies as an alternative energy source that crosses the BBB via a different transporter. The confirmatory test is a lumbar puncture showing hypoglycorrhachia: CSF/serum glucose ratio <0.4 (normal ≥0.6) in the absence of CNS infection. SLC2A1 sequencing confirms the genetic diagnosis.
4. A 9-month-old with recurrent prolonged febrile seizures is started on lamotrigine by a community pediatrician. Within weeks, the child has a prolonged convulsive episode requiring emergency treatment. Subsequent genetic testing reveals a pathogenic SCN1A variant. What is the most likely reason for the clinical deterioration?
This scenario illustrates a critical and unfortunately common clinical pitfall. SCN1A encodes the Nav1.1 sodium channel, which is preferentially expressed in inhibitory GABAergic interneurons. Haploinsufficiency (loss of function) means these inhibitory neurons fire less effectively, causing net brain hyperexcitability. Sodium channel blockers — including lamotrigine, oxcarbazepine, carbamazepine, and phenytoin — further suppress Nav1.1 activity in these already-impaired interneurons, worsening the excitatory/inhibitory imbalance and potentially precipitating status epilepticus. This is why early genetic diagnosis in epilepsy matters: it prevents harm from contraindicated medications. Preferred agents for Dravet syndrome include valproate, clobazam, stiripentol, fenfluramine, and cannabidiol.
5. A neonate with refractory seizures does not respond to an intravenous pyridoxine trial. The physician then administers pyridoxal-5-phosphate (PLP), and the seizures stop. Urine AASA levels are normal. Which diagnosis is most likely?
This scenario tests the critical distinction between pyridoxine-dependent epilepsy (PDE, caused by ALDH7A1) and PNPO deficiency. In PDE, the enzyme antiquitin is deficient, causing AASA to accumulate and inactivate PLP — but the pathway to convert pyridoxine → PLP is intact, so pyridoxine treatment works (and AASA is elevated). In PNPO deficiency, the enzyme that converts pyridoxine to its active form (pyridoxal-5-phosphate) is itself deficient — so giving pyridoxine does NOT work because the patient cannot convert it to PLP. PLP must be given directly. Crucially, AASA is NOT elevated in PNPO deficiency (antiquitin is normal). This distinction is clinically urgent: a neonate who fails pyridoxine should receive a PLP trial before concluding that vitamin-responsive epilepsy has been excluded.
6. Which statement best explains why genetic diagnosis is clinically important in epilepsy, beyond simply naming the condition?
Genetic epilepsy is one of the strongest examples of precision medicine in neurology. The same symptom — seizures — can be caused by opposite molecular mechanisms that require opposite treatments. Sodium channel blockers are first-line for KCNQ2 neonatal epilepsy but are contraindicated in SCN1A/Dravet syndrome. The ketogenic diet is the specific treatment for GLUT1 deficiency but is not routinely effective in most other genetic epilepsies. Vigabatrin achieves ~90–95% spasm cessation in TSC-associated infantile spasms but is not first-line for non-TSC spasms. Pyridoxine is lifesaving in ALDH7A1 deficiency. Beyond medication choice, genetic diagnosis informs prognosis, guides surveillance (e.g., cardiac monitoring in SCN1A), enables recurrence risk counseling, identifies contraindicated medications, and connects families with gene-specific research and clinical trials.